Tag
Breast cancer is the most common cancer among women, with 90% of patients belonging to high-risk groups. This article explores five major risk factors, early detection strategies, and lifestyle changes crucial for prevention.
This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.
A phase 3 trial demonstrates that a telephone-based lifestyle intervention achieves clinically significant weight loss in women with stage II/III breast cancer and overweight/obesity, with notable effectiveness across demographics, especial
This article reviews a patient-level meta-analysis on prolonging endocrine therapy for early breast cancer in postmenopausal women, focusing on the benefits of additional aromatase inhibitor treatment after five years of initial therapy.
A recent study shows that an AI system can detect interval breast cancers missed by radiologists on mammograms, potentially improving early diagnosis and screening outcomes in women with dense breasts.
This article explores the relationship between breast nodules and breast cancer, addressing common concerns and offering actionable health insights.
Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profil
Vepdegestrant, an oral PROTAC estrogen receptor degrader, significantly prolongs progression-free survival compared to fulvestrant in ESR1-mutant advanced breast cancer, but not in the overall ER+/HER2– population.
The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.
The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and
A single session of resistance or high-intensity interval training boosts anti-cancer myokines in breast cancer survivors, significantly suppressing cancer cell growth in vitro.
Adding 5 mg olanzapine after anthracycline-based chemotherapy significantly improves nausea and vomiting control with minimal sedation in breast cancer patients compared to standard antiemetic therapy alone.
A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.
Significant variation exists in bone health management for older women receiving endocrine therapy for breast cancer, highlighting the need for standardized care.
Antibody-drug conjugates (ADCs) have transformed breast cancer therapy but bring notable toxicity risks. This review examines the clinical evidence, adverse event management, and future directions for optimizing ADC use.
Eliminating a $45 fee for advanced breast cancer screening technology improves access and reduces health disparities, according to recent research.
Recent research highlights that estrogen-only hormone therapy may reduce breast cancer risk in women under 55, while combined estrogen-progestin therapy could increase risk.
